Aim: Patients with bipolar disorder (BD) tend to have poorer outcomes after pneumonia and could have a higher risk for recurrence of pneumonia. We aimed to investigate the incidence and risk factors of recurrent pneumonia in patients with BD.
general population, those with pneumonia have a high recurrence rate of about 9-12% and mortality ranging from 4% to 10%. [5] [6] [7] [8] Therefore, it is essential to prevent the recurrence of pneumonia for public health optimization. [9] [10] [11] [12] [13] Many lines of evidence suggest that patients with BD have a higher incidence of pneumonia with poorer outcomes, such as increased hospitalization rates compared with the general population.
14-21 To our knowledge, 22, 23 one of the independent risk factors for pneumonia in BD patients is treatment with antipsychotic drugs. Other possible associated risk factors include unhealthy lifestyle, biological factors, health-risk activities, and disparities in health care. 20, 21 Despite the detailed information on pneumonia in BD patients, there is little written on the incidence and potential risk factors of recurrent pneumonia in this group. It is unknown whether exposure to psychiatric medications would lead to higher risk of pneumonia recurrence in such patients. Furthermore, patients with BD have a high risk for comorbid medical illnesses, [24] [25] [26] [27] [28] but information is lacking regarding the association between the underlying medical illness and the risk of recurrent pneumonia in BD patients.
Accordingly, this study employed a large cohort of patients with BD with a history of pneumonia requiring hospitalization that was derived from a nationwide dataset in Taiwan. We investigated the incidence of recurring pneumonia in patients with BD and compared it with that in the general population. We conducted a nested case-control study to explore the possibility of psychiatric medications (including antipsychotics) increasing the incidence of recurrent pneumonia. Various dimensions of potential risk factors, including physical illnesses and concomitant drug use, were also comprehensively examined.
METHODS

Study population
The Taiwanese government implemented a singlepayer National Health Insurance program in 1995, and coverage of the 23 million Taiwanese people had reached 98% by the end of 2007. The National Health Research Institutes maintain the National Health Institutes Research Database (NHIRD), which is available to researchers upon application approval. Since the privacy of the insured patients is paramount to NHIRD use, the National Health Research Institutes encrypt the data to protect the identities of enrollees and health-care providers (http://w3.nhri.org.tw/ nhird/en/Data_Protection.html).
Ethics statement
Patient identification was protected by the confidentiality policy of the Bureau of National Health Insurance, Taiwan. All investigators signed an agreement guaranteeing patient confidentiality before using the database. This study conformed to the Declaration of Helsinki. It was approved by the Taipei City Hospital Review Board of the Committee on Human Subject Research. A waiver of informed consent was granted due to the minimal risk to the privacy of individual subjects, as the patient information was de-identified before the analysis.
BD cohort
The NHIRD contains the Psychiatric Inpatient Medical Claims database (PIMC), which includes patients whose admitting diagnosis, based on the ICD-9, included codes ranging from 290 to 319. The PIMC contained the records of 187 117 patients from 1 January 1996 to 31 December 2008. This database has been used for multiple research purposes other than pneumonia and psychiatric conditions. 22, 23 The veracity of the database is ensured by the periodic review and certification of each hospital that provides psychiatric inpatient services in Taiwan. The Taiwan Joint Commission on Hospital Accreditation, an independent, non-governmental organization, oversees hospital accreditation. The accreditation for qualified psychiatric services requires board-certified psychiatrists to diagnose inpatients.
We conducted a cohort study of patients with stable BD (ICD-9 codes 296.0 to 296.16, 296.4 to 296.81, and 296.89; n = 14 169) identified from the PIMC that were hospitalized between 1 July 1998 and 31 December 2006. Patients with the diagnosis of schizophrenia (ICD-9 code 295) were excluded. Each patient's diagnosis of BD was periodically verified until 31 December 2008 to confirm the stability of the diagnosis over time. Therefore, each subject had a consistent diagnosis of BD for at least 2 years. Additionally, eligible patients were limited to those newly diagnosed between 1 July 1998 and 31 December 2006, and those who had greater than 2 years of claims for inpatient and outpatient health-care services. Patients ranged in age from 15 to 65 years at their first psychiatric admission. Thus, a cohort of 9999 patients with BD was included in the study; this patient group was used in a previous study. 29 The patients' medical claims data between 1996 and 2012 were retrieved (Fig. 1 ). Patients readmitted with pneumonia and those who died or were censored within 30 days of hospital discharge after their first psychiatric admission were excluded (n = 116), similarly to other studies. 30, 31 Thus, the cohort consisted of 830 subjects with BD who had subsequent incident pneumonia during the study period. We collected the claims data of the insured beneficiaries enrolled in the study, including demographics, diagnoses, prescriptions, and health-care expenditures. The prescription records included the type and dosage of medication, time of prescription, and duration of therapy.
Nested case-control study
Among the patients in the BD cohort with pneumonia, those with subsequent recurring pneumonia that required hospitalization (ICD-9 codes 480-486 and 507) were classified as cases (n = 204, 22.65%). The average (SD, range) interval between the baseline pneumonia and recurring pneumonia episodes was 726.9 (682.8, 32-3441) days. The hospitalization date for the recurrent pneumonia episode was defined as the index date. For each case subject, we randomly selected two or fewer controls (no hospitalization for recurrent pneumonia) from the cohort according to a risk-set sampling strategy. The controls were matched by sex, age (AE5 years), and the year of baseline pneumonia hospitalization. Each control was then assigned the same index date as their matched case. The controls had at least one claim record after the assigned index date to verify that they were insured by the National Health Insurance program without censor (for example, death). We defined pneumonia to be fatal if the person died within 30 days after a recurrent pneumonia episode. 32, 33 The overview of this study design is provided in Figure S1 .
Potential risk factors
Several physical illnesses are associated with pneumonia recurrence, including asthma, diabetes mellitus, and others. 19, 31, 34, 35 Additionally, some medications are associated with recurrent pneumonia. 31 Thus, we investigated the effects of physical illnesses and medications taken for up to 180 days before the index date on the risk of recurrent pneumonia. The analysis also identified several potential confounders, such as the Charlson Comorbidity Index score at the baseline pneumonia admission and the number of psychiatric admissions during the 180 days before the baseline pneumonia hospitalization.
Drug exposure measurements
The risk of pneumonia is associated with the use of benzodiazepines, mood stabilizers, and antipsyc- All patients who were readmitted with pneumonia, died, or were otherwise censored within 30 days of discharge after their first psychiatric admission were excluded (n = 116)
Valid case-control pairs: for all pneumonia cases (n = 188) due to unavailability of controls for 16 cases hotics. 31 We collected data on the use of these psychiatric drugs and antidepressants (Appendix S1) from the prescription records and then determined the duration of treatment for each patient based on the number of units dispensed and the dosing regimen.
Each drug was commonly prescribed in Taiwan for the treatment of patients with BD. Drug exposure was measured using two categories in each case-controlled pair. We defined patients taking a specific drug within 30 days before the index date as 'current' users; the remaining patients were defined as 'noncurrent' users. The noncurrent group served as the reference group in the evaluation. We next calculated the risk of the specific drug on the development of pneumonia to show the timebased association between drug exposure and pneumonia.
We then estimated the association between the length of drug use in the current period and pneumonia and the relation between the accumulative defined daily dose (DDD) of the drug and pneumonia. The DDD was determined based on dosing information acquired from the Anatomical Therapeutic Chemical Classification System (ATC/DDD Index 2015. http://www.whocc.no/atc_ddd_index/ [accessed 6 June 2015]). For example, a DDD of clozapine was defined as 300 mg. A DDD of lithium was 24 mmole (or 890 mg), whereas one DDD of valproic acid was 1500 mg. 
Statistical analysis
The approximate incidence of recurrent pneumonia was estimated as the number of cases divided by the person-years contributed by all individuals in the cohort. We conducted a two-step multivariate, conditional logistic regression analysis. In the first step, we explored physical illnesses and concomitant medications as potential risk factors for recurrent pneumonia. The regression covariates included the Charlson Comorbidity Index 36,37 and the number of hospitalizations. We next conducted the multivariate regression based on the strategy of backward variable selection. The variables with a modest association (P < 0.20) were retained in the final model. The regression analysis was conducted using the Proc Phreg function of SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA). P-values of 0.05 or less were considered significant.
In the second stage, we investigated the effects of particular psychiatric drugs on the risk of pneumonia recurrence. We calculated the risk of pneumonia recurrence in relation to the current use of each specified drug by applying the factors in the first step as covariates.
Sensitivity analysis
We performed a sensitivity analysis to assess the strength of the results. To assure that using two controls did not deflate the statistical significance of the results, we repeated the analyses using four controls per case. The strategy for selecting four controls per case was the same as that for selecting two controls per case (risk-set sampling of the study cohort). In the main analysis, we did not use a case to control the ratio of 1:4 because the number of cases plus controls was nearly identical with the number of individuals in the cohort.
RESULTS
Characteristics of study subjects
The crude incidence of recurrent pneumonia was calculated as the number of incident cases divided by the contributed person-years of each person in the cohort (Table 1 ). The incidence of recurrent pneumonia was 6.60 cases per 100 person-years (95% confidence interval, 5.72-7.57, based on the Poisson distribution; 6597.7/100 000). The incidence of recurrent pneumonia increased with the increment of age. About one-tenth (9.24%) of the patients with recurrent pneumonia died within 30 days of hospitalization. The incidence of fatal recurrent pneumonia was 0.61 cases per 100 personyears (95% confidence interval, 0.37-0.96, based on the Poisson distribution).
As seen in Table 2 , the distributions for sex and age between cases and controls were similar. We observed no significant difference in the number of psychiatric admissions within 180 days before the baseline pneumonia. Cases and controls had comparable Charlson Comorbidity Index scores. More than 20% of cases and controls had two or more comorbid physical illnesses.
Physical illnesses and medications associated with recurrent pneumonia Table 3 shows the physical illnesses and concomitant medications contributing to the risk of recurrent pneumonia between cases and controls. Initially, between case subjects and controls, we used univariate conditional logistic regression to examine the distributions of unmatched factors. Thereafter, we conducted multivariate analysis and found that several comorbid physical illnesses were associated with the risk of recurrent pneumonia, including hypertension (adjusted risk ratio [aRR] = 2.38, P = 0.001), diabetes mellitus (aRR = 1.98, P = 0.004), cancer (aRR = 2.01, P = 0.050), and asthma (aRR = 2.92, P = 0.002). Additionally, cough and cold preparations were associated with an increased risk of recurrent pneumonia, with an aRR of 2.40 (P < 0.001).
Effects of antipsychotic agents and mood stabilizers on the risk of recurrent pneumonia Table 4 depicts the association between various psychiatric drugs (antipsychotics, mood stabilizers, antidepressants, and benzodiazepines) and risk of recurrent pneumonia. In the adjusted model, there was no significant association between any drug of interest and the risk of recurrent pneumonia. We furthermore investigated whether the duration and dosage of particular medications affected the recurrence of pneumonia. The results remained negative; for example, the risk ratios for the duration and cumulative dose of the current use of lithium were 0.99 (P = 0.271) and 0.99 (P = 0.883), respectively.
Sensitivity analysis
In the sensitivity analysis, the results were almost identical using four controls per case compared to using two controls per case (used in the study). Among the case-control pairs (1:4 ratio), with adjusting the covariates (Table S1 ), no significant association with the risk of recurrent pneumonia was found for any drug (Table S2) , except for carbamazepine. However, carbamazepine showed no significant dose-dependent relation with recurrent pneumonia in the univariate regression. For example, the risk ratios for the duration and cumulative dose of the current use of carbamazepine were 1.03 (P = 0.272) and 1.06 (P = 0.465), respectively. Thus, we conservatively cannot conclude that there is a significant association between carbamazepine and recurrent pneumonia.
DISCUSSION
To our knowledge, this study is the first to delineate an excess incidence of recurrent pneumonia in a nationwide cohort of patients with BD. Furthermore, the findings showed that several comorbid physical illnesses were associated with the risk of recurrent pneumonia in BD patients. Surprisingly, no individual psychotropic drug (antipsychotics, mood stabilizers, antidepressants, or benzodiazepines) increased this risk, which confirmed that in BD patients with a history of pneumonia, administration 
Incidence of recurrent pneumonia in BD
In the present cohort with BD, the incidence of recurrent pneumonia was 6.60 cases per 100 personyears, which is six times higher than the incidence of initial pneumonia (1.09 cases per 100 person-years) among the BD patients without a history of pneumonia. 22 In the general population, the risk of recurrent pneumonia was comparatively lower. Dang et al. 7 examined patients who were remitted from community-acquired pneumonia for at least 3 months and found that the incidence of recurrent pneumonia was 3.0/100 person-years (9.09% within 5 years). In another two related studies in Europe, 5, 6 the rate of recurrent pneumonia in the general population was similar (9.4%-9.69% within 3 years), which was much lower than that of our findings.
As we know, BD is related to higher rates of medical illnesses. 26 Crump and colleagues 19 reported that patients with BD had a greater risk of influenza, diabetes, cardiovascular disease, and stroke. Thus, the explanation for why patients with BD had an excess incidence of recurrent pneumonia could be the higher comorbidity rate of medical illness 26 in this group that leads to an increased risk of recurrent pneumonia.
Mortality of recurrent pneumonia in BD
The mortality data for recurrent pneumonia in the general population is scarce. Dang et al. 7 reported a fatality rate of 10.2% among those with recurrent pneumonia in a population-based prospective cohort study, which is similar to our finding in BD Table 2 ).
© 2018 The Authors Psychiatry and Clinical Neurosciences © 2018 Japanese Society of Psychiatry and Neurology patients (nearly 10%). However, the mean age of patients with recurrent pneumonia in the present study was 55.6 years, which is much younger than the average age of 72.1 years reported in the study by Dang et al. 7 Due to the risk of recurrent pneumonia related to the aging effect, 7 we deduced a fatality rate for patients with BD with recurrent pneumonia higher than that in the general population.
The literature documents the excessive mortality in BD patients derived from respiratory disease (such as pneumonia), which ranges from two to four times higher than that in the general population. [16] [17] [18] [19] [20] [21] 38 Patients with BD had a substantial burden of pneumonia, indicated by higher hospital-based mortality compared to that of control subjects. 39 As a result, disease burden of respiratory disease, including recurrent pneumonia, among patients with BD is not negligible; disease prevention at an early age in these patients is crucial.
Effect of physical illness and concomitant medications on the risk of recurrent pneumonia in BD
This study identified that patients with BD had increased risk of recurrent pneumonia if they had hypertension, diabetes mellitus, cancer, or asthma. These risk factors were similar to those of previous studies that have identified advanced age, physical illnesses (e.g., neurological disorder, heart failure, diabetes) as risk factors for recurrent pneumonia in the general population. [5] [6] [7] [40] [41] [42] [43] Chronic obstructive pulmonary disease (COPD) was identified as a risk factor for pneumonia. 8 In our study, COPD showed an increased risk ratio in the univariate conditional logistic regression but not in the multivariate analysis; thus, it was removed from multivariate regression.
A nationwide population-based cohort study in Denmark also revealed that BD was associated with increased risk of hospitalizations for COPD, asthma, pneumonia, congestive heart failure, and rehospitalization within 30 days for the same causing illness. 44 Moreover, patients with BD were often unaware of having physical abnormalities, leading to missed treatment opportunities. 45 Thus, identifying and mitigating these risk factors plays a crucial role in preventing the recurrence of pneumonia in patients with BD.
Regarding concomitant medications, only cough and cold preparations remained in the multivariate regression analysis in association with the risk of recurrent pneumonia. Recurrent pneumonia might not be diagnosed immediately, and in the early phase, it might present as an upper airway infection for which antitussives or other cold preparations are prescribed. Thus, this finding should be interpreted conservatively and needs future work to identify and understand it.
Prior research indicated that proton pump inhibitors (PPI) contributed to recurrent pneumonia in the general population. 43 PPI suppress gastric acid and promote bacterial recolonization, which helps to explain the phenomenon. 43 In our study, PPI contributed to an increased risk of recurrent pneumonia in the univariate analysis but not in the multivariate analysis; thus, PPI were removed from the multivariate regression analysis. Future replication of our work is needed to confirm the association with recurrent pneumonia.
No effect of psychiatric medications on the risk of recurrent pneumonia
One of the key findings in our study was the lack of an association between psychotropic medications (antipsychotics, mood stabilizers, antidepressants, and benzodiazepines) and recurrent pneumonia. In contrast, previous research showed that several antipsychotics, such as olanzapine, clozapine, and haloperidol, have an effect on incident pneumonia in BD patients. Additionally, in our recent study with schizophrenia, clozapine was associated with a dose-dependent increase regarding the risk of recurrent pneumonia. 31 Our explanations for the discrepancy are listed below. First, physical illnesses have a much more significant effect on recurrent pneumonia than that of psychiatric medications among patients with BD, which might have led to our negative results. Second, patients with BD are prescribed systemically lower doses of antipsychotic drugs, and rarely clozapine, compared to schizophrenia patients. Third, poor drug compliance in BD may lead to the observed difference.
Limitations
Several limitations should be considered when interpreting the results. First, we could not capture data from patients with pneumonia not warranting hospitalization, so that we may have underestimated the incidence of recurrent pneumonia. Second, adherence to the prescribed medication was not ascertained, which could have led to underestimation of the actual risk due to nondifferentiated misclassification of exposure. Third, data regarding potential confounders affecting the risk of recurrent pneumonia, such as obesity, behavioral profile (e.g., smoking and alcohol use), laboratory data (e.g., neutropenia), and pneumonia vaccination, were not available. Fourth, pneumonia can be induced by various etiologies, such as bacteria or viruses. Psychotropic drugs are known to disturb swallowing functions and potentially induce aspiration pneumonia. In this study, we included the cases with recurring pneumonia that required hospitalization (ICD-9 codes 480-486 and 507). Among the cases in valid case-control pairs (n = 188), the largest subcategory was bronchopneumonia, organism unspecified (ICD-9 code 486.**; n = 113), then pneumonia, organism unspecified (ICD-9 code 485.**; n = 21). Thus, we could not differentiate the specific causes of pneumonia; for example, whether the cause of the pneumonia was due to a bacterial or viral infection. Fifth, we investigated the associations between various psychiatric drugs (such as mood stabilizers, antipsychotics, antidepressants, and benzodiazepines) and the risk of recurrent pneumonia. However, due to limited sample size, the statistical power might not be high enough for a conclusion with null associations. Replication studies with a larger sample size are needed in the future for identifying these associations.
Conclusions
In this large nationwide cohort study, we found an excess incidence of recurring pneumonia in patients with BD, and this risk was associated with preexisting medical conditions but not psychotropic agents. Thus, identifying and mitigating pre-existing medical illness is crucial in preventing the recurrence of pneumonia in patients with BD.
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